Acute exacerbations of COPD due to pseudomonas aeruginosa: Impact of antimicrobial resistance Source: International Congress 2015 – Infection in COPD: different aspects of the host/pathogen balance Year: 2015
Outcome of multidrug resistant pulmonary tuberculosis Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010
Fosfomycin for pseudomonas related exacerbations of cystic fibrosis Source: Annual Congress 2008 - Cystic fibrosis: new mechanisms, monitoring and treatment tools Year: 2008
Pseudomonas aeruginosa and antibiotic resistance in acute exacerbations of COPD (AECOPD) Source: Annual Congress 2009 - Respiratory infection caused by Pseudomonas aeruginosa Year: 2009
Outcomes of patients with multidrug resistant tuberculosis Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005
Efficacy of ciprofloxacin against resistant mucoid or non-mucoid P. aeruginosa isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014
Multidrug resistant tuberculosis in non HIV patients Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases Year: 2007
Bacteria, antibiotics and COPD Source: Eur Respir J 2001; 17: 995-1007 Year: 2001
Susceptibility of Mycobacterium tuberculosis strains to fluoquinolones, obtained from chronic patients with multidrug resistant pulmonary tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 315s Year: 2001
Lipid profile in patients with multidrug resistant pulmonary tuberculosis Source: Eur Respir J 2002; 20: Suppl. 38, 361s Year: 2002
Pseudomonas aeruginosa drug susceptibility in patients hospitalized with COPD exacerbation and bronchiectasisSource: Eur Respir J 2001; 18: Suppl. 33, 541s Year: 2001
Eradication treatment in Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) on patients with pseudomonas aeruginosa Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections Year: 2017
Resistance to antimicrobial agents in patients with non-cystic fibrosis (CF) bronchiectasis Source: Eur Respir J 2005; 26: Suppl. 49, 640s Year: 2005
Characteristics of the cases with primary multidrug resistance pulmonary tuberculosis Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005
Susceptibility of problem respiratory pathogens to levofloxacin in cystic fibrosis (CF) Source: Eur Respir J 2002; 20: Suppl. 38, 526s Year: 2002
Multidrug resistance proteins and their significance in asthma bronchiale and nonspecific bowel dieases Source: Annual Congress 2008 - Miscellaneous respiratory infections Year: 2008
Inhaled colistin in elderly patients with bronchiectasis and chronic bronchial infection with pseudomonas Source: Annual Congress 2012 - Management of severe respiratory infections Year: 2012
Inhaled colistin in patients with non - cystic fibrosis bronchiectasis and chronic pseudomonas aeruginosa bronquial infection Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016
Severe exacerbations of chronic obstructive pulmonary disease (COPD) due to Pseudomonas aeruginosa : resistance to common antibiotics Source: Eur Respir J 2001; 18: Suppl. 33, 540s Year: 2001
The etiology and antimicrobial drugs resistance of microorganisms in patients with community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 2s Year: 2006